Clinical trials: Influenza Virus
Avian Influenza
A Safety and Immunogenicity Study of IVACFLU-A/H5N1
The study hypothesis was that two 0.5 mL doses of whole virion monovalent A/H5N1 influenza vaccine (IVACFLU-A/H5N1) adjuvanted with alum would be safe and well tolerated in healthy adults, and that at least one of the two doses…
- Trial name
- NCT02612909
- Testing
- IVACFLU-A/H5N1 vaccine
- Where
- 2 sites in Vietnam
- Volunteers
- 930 people, healthy volunteers welcome
- Sponsor
- Institute of Vaccines and Medical Biologicals, Vietnam
Influenza
Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older
This clinical trial aims to study the immunogenicity of GSK Biologicals' influenza vaccine GSK2186877A in people aged 65 years or older.
- Trial name
- NCT00765076
- Testing
- GSK Biologicals' influenza vaccine GSK2186877A, GSK Biologicals' Fluarix
- Where
- 4 sites in United States, Spain
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age
The purpose of this study is to characterize the safety and efficacy of GSK Biologicals' H1N1 flu candidate vaccines GSK2340274A and GSK2340273A in children 6 months to less than 10 years of age.
- Trial name
- NCT01051661
- Testing
- GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations), GSK Biologicals' investigational vaccine GSK2340273A (alternative formulations)
- Where
- 17 sites in Australia, Brazil and 6 more
- Volunteers
- 6,154 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Vaccine
A Study to Assess the Safety of ASP7374 in Adult Subjects Aged 20 or Older
The purpose of this study is to confirm the safety until Day 29 after injection of a single dose of quadrivalent vaccine ASP7374 in adult subjects aged 20 or older
- Trial name
- NCT02366962
- Testing
- ASP7374
- Where
- Japan
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- UMN Pharma Inc.
Influenza
Phase IV Trial to Collect Safety Data and Sera in Healthy Children Given Fluzone Vaccine
To provide serum to the Food and Drug Administration (FDA) for use by FDA, the Centers for Disease Control and Prevention (CDC), and the World Health Organization (WHO) for characterization of circulating influenza strains.
- Trial name
- NCT00258817
- Testing
- Influenza Virus Vaccine (Fluzone®)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Vaccine
A Study to Evaluate Intramuscular ASP7374
The purpose of this study is to evaluate safety and immunogenicity of intramuscular ASP7374 in adults ≥61 years of age.
- Trial name
- NCT01961960
- Testing
- ASP7374
- Where
- Japan
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- UMN Pharma Inc.
Influenza
Safety Study of Flufirvitide-3 Nasal Spray in Healthy Subjects
The purpose of this study is to evaluate the safety and pharmacokinetic profile of flufirvitide-3 nasal spray in healthy subjects.
- Trial name
- NCT01313962
- Testing
- Flufirvitide-3 0.05 mg single dose, Flufirvitide-3, 0.1 mg single dose, Flufirvitide-3, 0.2 mg single dose
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Autoimmune Technologies, LLC
Acellular Pertussis, Diphtheria
Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults
The current study will provide information for the use of Boostrix concomitantly with influenza vaccine in adults aged 19-64 years.
- Conditions
- Acellular Pertussis, Diphtheria, Tetanus
- Trial name
- NCT00385255
- Testing
- Fluarix®, Boostrix®
- Where
- 12 sites in United States
- Volunteers
- 1,726 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.
This is a study to assess the immune (antibody) response and safety of a bioCSL split virion, inactivated quadrivalent influenza vaccine, in comparison with a US licensed 2014/2015 trivalent influenza vaccine (bioCSL TIV-1), and…
- Trial name
- NCT02214225
- Testing
- Quadrivalent Influenza Vaccine (QIV), Trivalent Influenza Vaccine (TIV-1), Trivalent Influenza Vaccine (TIV-2)
- Where
- 33 sites in United States
- Volunteers
- 3,484 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza, Human
Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying MRNA Influenza Vaccine in Healthy Adults
This is a Phase 1, first-in-human, randomized, placebo-controlled, observer blind study. The effect of two doses of an investigational vaccine on safety, reactogenicity, kinetics and magnitude of the post-vaccination antibody…
- Trial name
- NCT06028347
- Testing
- sa-mRNA vaccine Dose 1, sa-mRNA vaccine Dose 2, sa-mRNA vaccine Dose 3
- Where
- 2 sites in Australia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly
Since influenza vaccines are normally administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profile of adjuvanted influenza vaccine need to be re-evaluated after…
- Trial name
- NCT00386113
- Testing
- Fluarix and adjuvanted influenza vaccine
- Where
- Belgium
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Bifidobacterium Lactis HN019 Supplementation for Prevention of Influenza Infection in Healthy Adults
To determine if prophylactic supplementation with B. lactis HN019 reduces the risk of developing physician- and laboratory-confirmed influenza infection at any time during the 12-week supplementation period.
- Trial name
- NCT01258842
- Testing
- Bifidobacterium lactis HN019
- Where
- 2 sites in United States
- Volunteers
- 426 people, healthy volunteers welcome
- Sponsor
- Fonterra Research Centre
Influenza
Study of Nitazoxanide in Adults With Acute Uncomplicated Influenza
This is a randomized clinical trial designed to evaluate oral nitazoxanide compared to a placebo in the treatment of acute uncomplicated influenza in adults.
- Trial name
- NCT01056380
- Testing
- Nitazoxanide
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Romark Laboratories L.C.
Influenza
A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination
To describe the safety of the inactivated, split-virion influenza vaccine, 2008-2009 formulation. To evaluate the compliance, in terms of immunogenicity, of the inactivated, split-virion influenza vaccine 2008-2009 formulation…
- Trial name
- NCT00743275
- Testing
- Split, Inactivated, Trivalent Influenza vaccine (Fluzone®)
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Human
Evaluation of Safety of GlaxoSmithKline (GSK) Vaccines' Quadrivalent Seasonal Influenza Vaccine, Fluarix Tetra When Administered According to the Approved Prescribing Information (PI) in Korea.
The purpose of this study is to collect safety information on the use of Fluarix Tetra according to the approved PI, in Korea, over a period of 6 years from children greater than or equal to (≥)3 years of age and adults, and over…
- Trial name
- NCT02663102
- Testing
- Data collection
- Where
- 21 sites in South Korea
- Volunteers
- 1,388 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID -19, Influenza A
Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings
The Metrix Respiratory Panel Test will be evaluated for use in Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein.
- Conditions
- COVID -19, Influenza A, Influenza B, Respiratory Synctial Virus
- Trial name
- NCT07217639
- Testing
- Aptitude Medical Systems Respiratory Panel Test
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Aptitude Medical Systems
Influenza
Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
This study is a global multicenter randomized factorial double-blind, placebo-controlled trial designed to evaluate (i) efficacy and safety of nitazoxanide 600 mg administered orally twice daily for five days compared to a…
- Trial name
- NCT01610245
- Testing
- Nitazoxanide, Oseltamivir
- Where
- 167 sites in United States, Australia and 3 more
- Volunteers
- 1,941 people
- Sponsor
- Romark Laboratories L.C.
Influenza
Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention Program
To measure the effectiveness of influenza vaccination in school children by comparing, between target(i.e., children are offered FluMist) and control (i.e., children are not offered FluMist) school families.
- Trial name
- NCT00192218
- Testing
- FluMist
- Where
- 2 sites in United States
- Volunteers
- 3,022 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intradermal Route)
The aim of this study is to evaluate the new formulation of the influenza vaccine for the 2010-2011 Northern Hemisphere (NH) season in terms of immunogenicity and safety in the corresponding population and to check its compliance…
- Trial name
- NCT01138397
- Testing
- Influenza virus vaccine (split virion, inactivated)
- Where
- 2 sites in Belgium
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza A Virus Infection
Interferon Alpha Lozenges Plus Oseltamivir for Influenza Treatment
This study aims to evaluate the safety and effect of interferon-alpha lozenges when used in combination with oseltamivir (Tamiflu) to treat influenza.
- Trial name
- NCT01146535
- Testing
- Interferon-alpha, Oseltamivir, maltose
- Where
- 4 sites in Taiwan
- Volunteers
- 40 people
- Sponsor
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.